Probiotic-based Treatment of Mastitis

Teagasc and University College Cork researchers are seeking a commercial partner within the animal health industry to exploit a novel technology involving the treatment of bovine mastitis with foodgrade probiotic bacteria – a natural and effective alternative to antibiotic therapy.

Summary
This technology represents a biological approach to mastitis prevention and is based on live foodgrade cultures of probiotic bacteria, specifically a proprietary strain of *Lactococcus lactis*, effective in treating animal and human infectious diseases and proven to be at least as effective as antibiotics, in the treatment of mastitis.

Problem Addressed
Current treatments for mastitis rely heavily on antibiotics, both for prophylaxis and therapy. This strategy is costly and frequently ineffective. Additionally there are concerns regarding the overuse of antibiotics in veterinary medicine, as it may contribute to the increased spread of antibiotic resistance to human and animal pathogens. Recent legislation in the EU curtailing the use of antibiotics in animal feed should lead to greater controls and limitations in their use. Use of antibiotics may be limited to situations where they are deemed critical.

Solution
There are several advantages to this treatment regime. The bacterium can be produced cheaply in large quantities and it is a foodgrade organism with GRAS status and hence should not require significant withholding periods for the milk produced by recovering animals, as in the case of treatment with antibiotics.

Competitive Advantage of Technology
1. Natural, effective alternative to antibiotic therapy for treatment of both mild and severe mastitis. Effective against mastitis caused by gram positive and negative bacteria.
2. Using live preparation, cure rates of subclinical and clinical infections were comparable to standard antibiotic therapy
3. Based on use of a foodgrade organism, significant withholding periods should not be required for milk produced by recovering animals, thereby reducing milk losses.

Opportunity
Mastitis causes significant economic losses to the dairy industry. Economic loss in Ireland is estimated at €189.56 per cow, in severe cases, and €45.31 in mild cases. Taking the average incidence of mastitis as 25%, a mean economic value per case of mastitis of €71.84 is estimated (EBI 2007). With an Irish dairy herd population of 1.1m, this gives an estimated annual cost of €20m in Ireland alone.

This represents a significant opportunity for an animal health company to validate and commercialise this technology.

Intellectual Property Status
Patent granted in US and in selected European countries, “Use of Probiotic bacteria in treatment of infection”.

Partners

Funding

How to Proceed:
For further information contact:
Miriam Walsh
Tel: +353 (0)59 9183477
Email: miriam.walsh@teagasc.ie